These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18199530)

  • 1. Revealing targeted therapy for human cancer by gene module maps.
    Wong DJ; Nuyten DS; Regev A; Lin M; Adler AS; Segal E; van de Vijver MJ; Chang HY
    Cancer Res; 2008 Jan; 68(2):369-78. PubMed ID: 18199530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denoising perturbation signatures reveal an actionable AKT-signaling gene module underlying a poor clinical outcome in endocrine-treated ER+ breast cancer.
    Teschendorff AE; Li L; Yang Z
    Genome Biol; 2015 Apr; 16(1):61. PubMed ID: 25886003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
    Mitsiades CS
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S23-7. PubMed ID: 19795532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.
    Deeb KK; Michalowska AM; Yoon CY; Krummey SM; Hoenerhoff MJ; Kavanaugh C; Li MC; Demayo FJ; Linnoila I; Deng CX; Lee EY; Medina D; Shih JH; Green JE
    Cancer Res; 2007 Sep; 67(17):8065-80. PubMed ID: 17804718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
    Milani M; Rzymski T; Mellor HR; Pike L; Bottini A; Generali D; Harris AL
    Cancer Res; 2009 May; 69(10):4415-23. PubMed ID: 19417138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic pathway signatures in human cancers as a guide to targeted therapies.
    Bild AH; Yao G; Chang JT; Wang Q; Potti A; Chasse D; Joshi MB; Harpole D; Lancaster JM; Berchuck A; Olson JA; Marks JR; Dressman HK; West M; Nevins JR
    Nature; 2006 Jan; 439(7074):353-7. PubMed ID: 16273092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H; Khayat D; Giaccone G; Facon T
    Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
    Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
    Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery, Development, and clinical applications of bortezomib.
    Jung L; Holle L; Dalton WS
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proteasome and proteasome inhibitors in cancer therapy.
    Voorhees PM; Orlowski RZ
    Annu Rev Pharmacol Toxicol; 2006; 46():189-213. PubMed ID: 16402903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
    Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Fanourakis G; Gu X; Bailey C; Joseph M; Libermann TA; Treon SP; Munshi NC; Richardson PG; Hideshima T; Anderson KC
    Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14374-9. PubMed ID: 12391322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification association of drug-disease by using functional gene module for breast cancer.
    Zhu L; Zhu F
    BMC Med Genomics; 2015; 8 Suppl 2(Suppl 2):S3. PubMed ID: 26045063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Coleman M
    Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.
    Dubois D; Dhawan R; van de Velde H; Esseltine D; Gupta S; Viala M; de la Loge C
    J Clin Oncol; 2006 Feb; 24(6):976-82. PubMed ID: 16432077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J; Cibeira MT; Rosiñol L
    Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
    An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
    Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable outcome associated with an IGF-1 ligand signature in breast cancer.
    Mu L; Tuck D; Katsaros D; Lu L; Schulz V; Perincheri S; Menato G; Scarampi L; Harris L; Yu H
    Breast Cancer Res Treat; 2012 May; 133(1):321-31. PubMed ID: 22297468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.
    Politou M; Karadimitris A; Terpos E; Kotsianidis I; Apperley JF; Rahemtulla A
    Leuk Res; 2006 Feb; 30(2):240-1. PubMed ID: 16081156
    [No Abstract]   [Full Text] [Related]  

  • 20. Correlating transcriptional networks with pathological complete response following neoadjuvant chemotherapy for breast cancer.
    Liu R; Lv QL; Yu J; Hu L; Zhang LH; Cheng Y; Zhou HH
    Breast Cancer Res Treat; 2015 Jun; 151(3):607-18. PubMed ID: 25981901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.